chemoresponse

che·mo·re·sponse

(kē'mō-rē-spontz'),
A reaction to chemical stimulation.

che·mo·re·sponse

(kē'mō-rĕ-spons')
Areaction to chemical stimulation.
References in periodicals archive ?
Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse," Journal of Clinical Oncology, vol.
TP53 mutations and survival in osteosarcoma patients: a meta-analysis of published data
Combining whole genome miRNA/mRNA sequencing, bioinformatics and network biology, miRNAs/their target network involved in chemoresistance will be identified, and targeted to enhance the chemoresponse of TNBC models.
TNBCHEMIRNET: Enhancing chemotherapy response in triple negative breast cancer (TNBC) by modulating miRNA-target network and identifying biomarkers of response
24 February 2014 - US diagnostics services company Precision Therapeutics Inc reported Monday study findings showing that its ChemoFx chemoresponse assay can detect resistance to first-line therapy in ovarian cancer.
Precision Therapeutics' ChemoFx test can find resistance to first-line therapy in ovarian cancer patients
Effects of liquid growth versus plate growth of Caenorhabditis elegans on chemoresponse to pathogenic bacteria.
Abstracts of Poster Presentations at the 2012 ([122.sup.ND]) Annual Meeting of the Tennessee Academy of Science
57) Induction chemotherapy before definitive surgery allows us to assess the chemoresponse in resected specimens, which has some prognostic significance and has a role in selection of agents for continuation chemotherapy.
Small round cell tumors of bone
1:20-1:40 pm Bin Guo * BCL-G IN APOPTOSIS AND CHEMORESPONSE OF
ND BRIN Professional Session: Crystal Ballroom
A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy examined 42 breast cancer cell lines by using the ChemoFx in-vitro chemoresponse test after treatment with two widely used standard combination chemotherapies for breast cancer.
ChemoFx[R] Used to Develop Multi-Gene Predictors to Chemotherapy in Breast Cancer
PITTSBURGH -- In Vitro Chemoresponse Assessment of Optimally and Sub-Optimally Debulked Primary Ovarian Cancer,a studysubmitted by Dr.
ChemoFx Results Show Differences in Chemoresponse between Optimally and Sub-Optimally Debulked Primary Ovarian Cancers
Grigsby and titled, In Vitro Chemoresponse Analysis and Clinical Outcomes in Cervical Cancer.
New Study Shows Association between ChemoFx[R] Results and Recurrence Free Survival
In Vitro Chemoresponse in Metachronous Pairs of Gynecologic Cancers, recently presented in poster form at the British Gynaecological Cancer Society (BGCS) Annual Meeting held July 5-6, 2012, was conducted by Dr.
Precision Therapeutics' ChemoFx[R] Test Useful in Determining Treatment for Resistant and Recurrent Gynecologic Cancer Patients
Grigsby and titled, In Vitro Chemoresponse Analysis and Clinical Outcomes in Cervical Cancer,reports the association between ChemoFx test results and recurrence-free survival (RFS) of cervical cancer patients.
Four Abstracts on ChemoFx[R] to Be Presented at IGCS Annual Meeting
The study titled, In Vitro Chemoresponse Assay Results and Population Clinical Response Rates in Women with Ovarian Cancer, begins to answer the clinical question of whether the ChemoFx([R]) in vitro drug response marker can be used to help determine tumor response to platinum chemotherapy agents.
ChemoFx[R] Provides Tumor-Specific Information That May Assist in Personalized Chemotherapy Selection
Medical browser ?
Full browser ?